文献速递瓣膜外科先天性心脏病外科

去细胞同种主动脉瓣用于儿童主动脉瓣置换:143例植入的多中心五年随访更新

Paediatric aortic valve replacement using decellularized allografts: a multicentre update following 143 implantations and five-year mean follow-up.
PubMed 文献 · Eur J Cardiothorac Surg · 2024-01-01

该研究前瞻性多中心随访8个欧洲中心2008年2月至2023年2月137例儿童(143枚去细胞主动脉同种移植物DAH),中位随访5.3年,5年免于死亡/移植物取出/感染性心内膜炎/出血/血栓栓塞分别为97.8±1.2%/88.7±3.3%/99.1±0.9%/100%和99.2±0.8%,结论为DAH中期生存优良且不良事件率与儿童Ross手术相当。

要点

  • 143枚DAH植入137例儿童,中位年龄10.8岁,中位随访5.3年,5年免于移植物取出88.7±3.3%。
  • 5年免于死亡97.8±1.2%、感染性心内膜炎99.1±0.9%、出血100%、血栓栓塞99.2±0.8%。
  • 21枚DAH被取出,其中13例再次植入DAH无再手术死亡,结论称不良事件率与儿童Ross手术相当。

核心结论

  • 这项大规模前瞻性分析显示使用DAH的中期生存优良,不良事件率与儿童Ross手术相当。

研究设计与样本

  • 前瞻性多中心随访研究,纳入8个欧洲中心所有接受DAH行主动脉瓣置换的儿童患者,共137例儿童植入143枚DAH。

主要发现

  • 2008年2月至2023年2月共植入143枚DAH,137例儿童中106例(74%)为男性,中位年龄10.8岁(四分位距6.6-14.6)。
  • 84例(59%)有既往心脏手术史,24例(17%)有既往主动脉瓣置换史,植入DAH中位直径21 mm(四分位距19-23)。
  • 中位手术时间348 min(227-439),中位体外循环时间212 min(171-257),中位主动脉阻断时间135 min(113-164)。
  • 中位随访5.3年(3.3-7.2,最长15.2年)时,主要疗效终点峰值压差中位14 mmHg(9-28)、反流中位0.5(四分位距0-1,0-3级)结果良好但随时间增加。
  • 5年免于死亡/移植物取出/感染性心内膜炎/出血/血栓栓塞分别为97.8±1.2%/88.7±3.3%/99.1±0.9%/100和99.2±0.8%,10年分别为96.3±1.9%/67.1±8.0%/93.6±3.9%/98.6±1.4和86.9±11.6%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Decellularized aortic homografts (DAH) were introduced in 2008 as a further option for paediatric aortic valve replacement (AVR). METHODS: Prospective, multicentre follow-up of all paediatric patients receiving DAH for AVR in 8 European centres. RESULTS: A total of 143 DAH were implanted between February 2008 and February 2023 in 137 children (106 male, 74%) with a median age of 10.8 years (interquartile range 6.6-14.6). Eighty-four (59%) had undergone previous cardiac operations and 24 (17%) had undergone previous AVR. The median implanted DAH diameter was 21 mm (interquartile range 19-23). The median operation duration was 348 min (227-439) with a median cardiopulmonary bypass time of 212 min (171-257) and a median cross-clamp time of 135 min (113-164). After a median follow-up of 5.3 years (3.3-7.2, max. 15.2 years), the primary efficacy end-points peak gradient (median 14 mmHg, 9-28) and regurgitation (median 0.5, interquartile range 0-1, grade 0-3) showed good results but an increase over time. Freedom from death/explantation/endocarditis/bleeding/thromboembolism at 5 years were 97.8 ± 1.2/88.7 ± 3.3/99.1 ± 0.9/100 and 99.2 ± 0.8%, respectively. Freedom from death/explantation/endocarditis/bleeding/thromboembolism at 10 years were 96.3 ± 1.9/67.1 ± 8.0/93.6 ± 3.9/98.6 ± 1.4 and 86.9 ± 11.6%, respectively. In total, 21 DAH were explanted. Seven were replaced by a mechanical AVR, 1 Ross operation was performed and a re-do DAH was implanted in 13 patients with no redo mortality. The calculated expected adverse events were lower for DAH compared to cryopreserved homograft patients (mean age 8.4 years), and in the same range as for Ross patients (9.2 years) and mechanical AVR (13.0 years). CONCLUSIONS: This large-scale prospective analysis demonstrates excellent mid-term survival using DAH with adverse event rates comparable to paediatric Ross procedures.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Horke A, Bobylev D, Avsar M, et al. Paediatric aortic valve replacement using decellularized allografts: a multicentre update following 143 implantations and five-year mean follow-up. Eur J Cardiothorac Surg. 2024. PMID: 38532286. doi:10.1093/ejcts/ezae112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。